Structure Encountered
Dragonfly Therapeutics
Develops natural killer cell engagers and engineered cytokines for oncology and autoimmune disease
Dragonfly's DF5112 (CCR6 depletor) completed IV cohorts with depletion of both Th17 and B cells, now advancing to subcutaneous dosing. PsA, Sjögren's, SSc, HS on the indication shortlist.
SIGNAL·Phase 1 clinical update (IV→SC transition with PD readout)·First subcutaneous patient dosed in Phase 1 for DF5112; IV dosing phase complete and showed depletion of both Th17 cells and B cells. No efficacy percentages, enrollment counts, or response rates disclosed.·SCORE 78·19 MAY 2026 · 12:47 UTC
● CAPTURE — IMAGE INCOMINGFRAME 01 / 01
STRUCT. / DRAGONFLY THERAPEUTICS
/ Waltham, Massachusetts, United States
CAPT. / 19.05.26 12:47:05Z
SIGNAL / 78 / 100
Image relayed by The Biotech Voyager during pass over structure Dragonfly Therapeutics. Resolution as transmitted.
001Vital Statistics
DATA LOCKED
Designation
Dragonfly Therapeutics
Coordinates
Waltham, Massachusetts, United States
Stage
Phase 2
Type
Therapeutics
Modalities
biologic · NK cell engager · protein therapeutic · antibody
Therapeutic area
Oncology · Autoimmune · Immunology
002Signature Detected
EVENT DETECTED
Event type
Phase 1 clinical update (IV→SC transition with PD readout)
Magnitude
First subcutaneous patient dosed in Phase 1 for DF5112; IV dosing phase complete and showed depletion of both Th17 cells and B cells. No efficacy percentages, enrollment counts, or response rates disclosed.
Lead
Dragonfly Therapeutics (sponsor)
Participating
None disclosed
Use of capital
N/A (no financing event); program funded internally from prior >$300M equity + partnership capital base.
003Architecture
PLATFORM PROFILE
Target class
CCR6 chemokine receptor (Th17 cell homing receptor; mechanism also depletes B cells)
Differentiator
CCR6 isn't a depleter target most companies are working on. CCR6 is the homing receptor for Th17 cells, the same cells that drive psoriasis, psoriatic arthritis, and several other autoimmune conditions. Dragonfly's TriNKET platform is built for cancer; using it to deplete an autoimmune cell population (and B cells as a bonus) is a platform pivot. IV phase dosing already showed depletion of both Th17 and B cells. That's a wider B cell + Th17 sweep than what IL-17 or IL-23 antibodies deliver.
Lead asset
DF5112 (CCR6-targeting biologic that depletes Th17 cells and B cells; Phase 1, NCT07232121, n=64 planned across IV and SC cohorts)
Pipeline depth
Five wholly-owned clinical assets: DF1001 (HER2 TriNKET, Phase 2 solid tumors, n=378), DF9001 (EGFR TriNKET, Phase 1/2 complete in 24 patients), DF6002 (IL-12 cytokine, Phase 1), DF6215 (IL-2 cytokine, Phase 1, n=255 in solid tumors), DF5112 (CCR6 depletor, Phase 1). Partnered programs at Merck, BMS, AbbVie, Gilead spanning eight clinical candidates.
004Voyager Assessment
MACHINE-GENERATED
A CCR6 depletor that hits both Th17 cells and B cells is a wide net. Psoriatic arthritis, Sjögren's, systemic sclerosis, and hidradenitis suppurativa all sit in spaces where IL-17 and B cell biology overlap. The interesting platform story is that Dragonfly built the TriNKET engine for cancer NK cell engagement and is now using a related modality to deplete autoimmune cell populations. With SC dosing now in cohorts and the IV phase already producing a clean Th17 + B cell depletion signal, the question is which indication Dragonfly picks for Phase 2.
005Adjacent Structures
FRONTIER MAP
Cullinan Therapeutics· CD19/CD3 TCE for autoimmuneKali Therapeutics· CD19/BCMA/CD3 trispecific autoimmuneOuro Medicines· BCMA×CD3 TCE for autoimmune (Galapagos-Gilead)Roche/Genentech· CD20 deep B cell depleterNovartis· psoriatic arthritis IL-17 incumbentJohnson & Johnson· Tremfya IL-23 standardEli Lilly· Th17 IL-17A asthma/psoriasis incumbentAnaptysBio· B cell depleter for autoimmune
— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.